RecruitingNCT00001373
Immune
Familial Mediterranean Fever
Also known as FMF, MEF, recurrent polyserositis, MEFV mutation
Familial Mediterranean Fever is the most common hereditary periodic fever syndrome, caused by gain-of-function mutations in MEFV encoding pyrin, a protein integral to inflammasome regulation, resulting in episodic uncontrolled interleukin-1
ORPHA:342 ↗Gene MEFVPrevalence 1 in 200-1,000 in high-risk Mediterranean populations; 1 in 100,000 globallyOnset Childhood, typically before age 20Autoinflammatory periodic fever syndrome
39
studies recruiting now
as of 7 Sept 2026
241
studies registered in total
as of 7 Sept 2026
25
countries with a recruiting site
as of 7 Sept 2026
14 Jul 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 3NCT04528082
Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease
RecruitingPhase 1NCT06371417
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
RecruitingNot applicableNCT07702123
Efficacy of Physical Activity Program in Metabolic-syndrome Females With Behcet Disease
RecruitingNot applicableNCT07702149
Diet Restiction in Subjects With Behcet Disease and Complaint of Tinnitus
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 39 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Familial Mediterranean Fever study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: Eurofever Registry · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Familial Mediterranean Fever
Familial Mediterranean Fever is the most common hereditary periodic fever syndrome, caused by gain-of-function mutations in MEFV encoding pyrin, a protein integral to inflammasome regulation, resulting in episodic uncontrolled interleukin-1 beta-mediated inflammation. Characteristic attacks of fever lasting 1-3 days are accompanied by serositis (peritoneal, pleural, or synovial), and attacks recur unpredictably throughout life. The most serious long-term complication is AA amyloidosis from chronic subclinical inflammation, which can lead to renal failure if colchicine therapy is insufficient or delayed.
Common clinical features
Recurrent febrile episodes lasting 1-3 daysSevere abdominal pain from sterile peritonitisPleuritis causing chest painAcute arthritis (usually monoarticular, lower limb)Erysipelas-like erythema on the lower legsElevated acute-phase reactants (CRP, SAA) between attacksAA amyloidosis with proteinuria in untreated or refractory cases
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
2 approved treatments and 6 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Canakinumab (Ilaris)Approved: Colchicine (Colchicine component of col-probenecid)
Phase 3Anakinra (Antril)
Phase 2Rilonacept (Arcalyst)
Phase 2Vimnerixin
Phase 2Goflikicept
Phase 2Tocilizumab (Actemra roactemra)
Phase 2Sodium Chloride (Aqsia (balanced salt soln))
Before you apply
Things trial teams commonly ask about for Familial Mediterranean Fever. Not eligibility rules; those are set by each study.
- Colchicine resistance or intolerance is the primary eligibility gate for IL-1 inhibitor trials (anakinra, canakinumab, rilonacept); document colchicine dose, duration, and reason for inadequate response
- Renal function and 24-hour urine protein are screened in most trials to assess amyloid burden; have current nephrology assessments available
- Attack frequency documentation (diary records showing at least 4-6 attacks per year) is typically required to confirm disease activity for interventional trial enrollment
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).